News
As the FDA’s ban on mass compounding of semaglutide takes effect, Novo Nordisk introduces discounted pricing and new patient ...
Novo's Wegovy has lost market share to Eli Lilly's Zepbound, and a new head-to-head study found that Zepbound patients lost ...
The U.S. Environmental Protection Agency has drafted a plan to eliminate all limits on greenhouse gases from coal and ...
Eli Lilly’s Zepbound proved more effective than Novo Nordisk’s Wegovy in a new head-to-head trial, though both medications ...
Online prescriptions – for everything from weight loss to medicinal cannabis – is now a big business backed by Woolworths and ...
22h
Zacks Investment Research on MSN3 Stocks Targeting Weight Loss Market With Cannabinoid-Based TherapiesThe obesity market has garnered much interest lately, propelled by the success of GLP-1 therapies Wegovy and Zepbound, marketed by pharma giants Novo Nordisk NVO and Eli Lilly LLY, respectively. This ...
As demand for GLP-1 weight-loss medications like Wegovy and Zepbound continues to grow in the United States, so do questions about their affordability.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results